Novo Nordisk ADR (NYSE: NVO) kicked off on November 20, 2023, at the price of $101.50, up 2.17% from the previous trading day. During the day, the shares moved up to $103.74 and dropped to $101.49 before settling in for the closing price of $101.39. Over the past 52 weeks, NVO has traded in a range of $56.07-$104.00.
A company in the Healthcare sector has jumped its sales by 8.19% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 45.43%. With a float of $3.39 billion, this company’s outstanding shares have now reached $3.42 billion.
In an organization with 54393 employees, it is important to assess its efficiency. In terms of profitability, gross margin is +82.50, operating margin of +42.06, and the pretax margin is +39.14.
Novo Nordisk ADR (NVO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Novo Nordisk ADR is 0.00%, while institutional ownership is 8.89%.
Novo Nordisk ADR (NVO) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/29/2023, the organization reported $0.73 earnings per share (EPS), higher than consensus estimate (set at $0.73) by $0. This company achieved a net margin of +31.38 while generating a return on equity of 72.00. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.80% during the next five years compared to 8.17% growth over the previous five years of trading.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Take a look at Novo Nordisk ADR’s (NVO) current performance indicators. Last quarter, stock had a quick ratio of 0.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.39. Likewise, its price to free cash flow for the trailing twelve months is 28.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 4.08, a number that is poised to hit 0.65 in the next quarter and is forecasted to reach 3.16 in one year’s time.
Technical Analysis of Novo Nordisk ADR (NVO)
Let’s dig in a bit further. During the last 5-days, its volume was 5.21 million. That was better than the volume of 3.42 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 73.70%. Additionally, its Average True Range was 2.73.
During the past 100 days, Novo Nordisk ADR’s (NVO) raw stochastic average was set at 98.56%, which indicates a significant increase from 98.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.18% in the past 14 days, which was lower than the 37.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $96.37, while its 200-day Moving Average is $84.70. However, in the short run, Novo Nordisk ADR’s stock first resistance to watch stands at $104.39. Second resistance stands at $105.19. The third major resistance level sits at $106.64. If the price goes on to break the first support level at $102.14, it is likely to go to the next support level at $100.69. The third support level lies at $99.89 if the price breaches the second support level.
Novo Nordisk ADR (NYSE: NVO) Key Stats
The company with the Market Capitalisation of 350.83 billion has total of 4,487,532K Shares Outstanding. Its annual sales at the moment are 25,057 M in contrast with the sum of 7,862 M annual income. Company’s last quarter sales were recorded 8,575 M and last quarter income was 3,282 M.